Levodopa and childhood amblyopia

Area of Science:

• Ophthalmology
• Neuroscience
• Pharmacology

Background:

• Amblyopia, or "lazy eye," often persists in older children despite conventional treatments like occlusion therapy.
• Exploring novel pharmacological interventions is crucial for refractory amblyopia cases.

Purpose of the Study:

• To evaluate the safety and efficacy of levodopa/carbidopa in treating amblyopia in children resistant to standard therapies.
• To assess the pharmacokinetic profile and visual function improvements following drug administration.

Main Methods:

• A pilot study involving five amblyopic children (7-12 years) and two adults receiving escalating doses of levodopa/carbidopa.
• Monitoring of vital signs, adverse events, and blood samples for pharmacokinetic analysis.
• Assessment of visual acuity, contrast sensitivity, stereo acuity, and pattern visual evoked responses (VERs).

Main Results:

• Significant temporary improvements in Snellen visual acuity (20/159 to 20/83) and contrast sensitivity were observed in amblyopic eyes.
• Pharmacokinetics showed peak levodopa serum levels within 1 hour, with a 50% decrease by 2-4 hours.
• High incidence of side effects, including nausea and emesis (4/7 subjects), and transient visual function improvements lasting up to 5 hours.

Conclusions:

• Levodopa/carbidopa demonstrated temporary visual function enhancement in older amblyopic children.
• The drug's tolerability and side effect profile require careful consideration for future therapeutic development.
• Results support the rationale for a larger clinical trial investigating levodopa/carbidopa for childhood amblyopia.